Liraglutide Injection
Product Images NDC 0143-9144

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 0143-9144). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 Structural Formula Of Liraglutide (Liraglutide Injection 1)

Figure 1 Structural Formula Of Liraglutide (Liraglutide Injection 1)
FDA Label Image

Flow Check Symbol (Liraglutide Injection 10)

Flow Check Symbol (Liraglutide Injection 10)
FDA Label Image

Fig. E (Liraglutide Injection 11)

Fig. E (Liraglutide Injection 11)
FDA Label Image

Figure F (Liraglutide Injection 12)

Figure F (Liraglutide Injection 12)
FDA Label Image

Figure G (Liraglutide Injection 13)

Figure G (Liraglutide Injection 13)
FDA Label Image

Figure H (Liraglutide Injection 14)

Figure H (Liraglutide Injection 14)
FDA Label Image

Figure I (Liraglutide Injection 15)

Figure I (Liraglutide Injection 15)
FDA Label Image

Figure J And K (Liraglutide Injection 16)

Figure J And K (Liraglutide Injection 16)
FDA Label Image

Fig. L (Liraglutide Injection 17)

Fig. L (Liraglutide Injection 17)
FDA Label Image

Fig. M (Liraglutide Injection 18)

Fig. M (Liraglutide Injection 18)
FDA Label Image

Figure N (Liraglutide Injection 19)

Figure N (Liraglutide Injection 19)
FDA Label Image

Figure 2 Mean Insulin Secretion Rate (isr) Versus Glucose Concentration Following Single-dose Liraglutide Injection 7.5 Mcg/kg (~ 0.7 mg) Or Placebo In Patients With Type 2 Diabetes (n=10) During Graded Glucose Infusion (Liraglutide Injection 2)

Figure 2 Mean Insulin Secretion Rate (isr) Versus Glucose Concentration Following Single-dose Liraglutide Injection 7.5 Mcg/kg (~ 0.7 mg) Or Placebo In Patients With Type 2 Diabetes (n=10) During Graded Glucose Infusion (Liraglutide Injection 2)
This text contains data related to the plasma glucose levels in a study involving injections of liraglutide and a placebo. The values show measurements in milligrams per deciliter (mg/dL) at different time points. The data seems to represent a graph or chart, showing blood glucose levels at various intervals.*
FDA Label Image

Figure O (Liraglutide Injection 20)

Figure O (Liraglutide Injection 20)
FDA Label Image

Figure P (Liraglutide Injection 21)

Figure P (Liraglutide Injection 21)
FDA Label Image

Figure Q (Liraglutide Injection 22)

Figure Q (Liraglutide Injection 22)
FDA Label Image

Carton 3pk-268108-6 (Liraglutide Injection 23)

Carton 3pk-268108-6 (Liraglutide Injection 23)
Not available*
FDA Label Image

Carton 2pk-268109-6 (Liraglutide Injection 24)

Carton 2pk-268109-6 (Liraglutide Injection 24)
This is a description of Liraglutide Injection, available in two concentrations: 5 mg/mL and 6 mg/mL. It comes in a pen for single patient use only. It is advised to refrigerate and not freeze the product. The injection contains 5.5 mg of Liraglutide and water for injection. Each package includes a Medication Guide. This information is useful for healthcare professionals and pertains to the proper storage and administration of the medication.*
FDA Label Image

Figure 3 Mean Hba1c For Patients Who Completed The 52-week Trial And For The Last Observation Carried Forward (locf, Intent-to-treat) Data At Week 52 (monotherapy) (Liraglutide Injection 3)

Figure 3 Mean Hba1c For Patients Who Completed The 52-week Trial And For The Last Observation Carried Forward (locf, Intent-to-treat) Data At Week 52 (monotherapy) (Liraglutide Injection 3)
This text appears to contain information regarding a comparison study between 4 mg of Glimepiride and Liraglutide Injection at doses of 1.2 mg and 1.8 mg. The study assesses the mean HbA1c (%) levels over time in weeks. The analysis may involve ANCOVA to compare the effectiveness of the different treatments on reducing HbA1c levels.*
FDA Label Image

Figure 4 Mean Hba1c For Patients Who Completed The 26-week Trial And For The Last Observation Carried Forward (locf, Intent-to-treat) Data At Week 26 (Liraglutide Injection 4)

Figure 4 Mean Hba1c For Patients Who Completed The 26-week Trial And For The Last Observation Carried Forward (locf, Intent-to-treat) Data At Week 26 (Liraglutide Injection 4)
FDA Label Image

Liraglutide Injection Pen Diagram (Liraglutide Injection 5)

Liraglutide Injection Pen Diagram (Liraglutide Injection 5)
This is a description for Liraglutide Injection Pen. If you are experiencing difficulties with the device, you can reach out to Hikma Pharmaceuticals USA Inc. at 877-845-0689 for assistance.*
FDA Label Image

Figure A (Liraglutide Injection 6)

Figure A (Liraglutide Injection 6)
FDA Label Image

Figure B (Liraglutide Injection 7)

Figure B (Liraglutide Injection 7)
FDA Label Image

Figure C (Liraglutide Injection 8)

Figure C (Liraglutide Injection 8)
FDA Label Image

Figure D (Liraglutide Injection 9)

Figure D (Liraglutide Injection 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.